Eliem cuts in on Tango, proposing acquisition after strategic review

Eliem Therapeutics is sashaying away from the brink of closure, joining hands with Tango Therapeutics after reviewing strategic alternatives.

Eliem is set to snap up oncology-focused Tango, according to Securities and Exchange Commission documents filed March 18. Both companies have funds affiliated with RA Capital.